256 related articles for article (PubMed ID: 23918612)
1. Phase 2 study of a high dose of 186Re-HEDP for bone pain palliation in patients with widespread skeletal metastases.
Pirayesh E; Amoui M; Mirzaee HR; Tabei F; Rakhsha A; Kalantari BA; Shafiei B; Assadi M; Asli IN
J Nucl Med Technol; 2013 Sep; 41(3):192-6. PubMed ID: 23918612
[TBL] [Abstract][Full Text] [Related]
2. [186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast.
Minutoli F; Herberg A; Spadaro P; Restifo Pecorella G; Baldari S; Aricò D; Altavilla G; Baldari S
Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):355-62. PubMed ID: 17043634
[TBL] [Abstract][Full Text] [Related]
3. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
Liepe K; Hliscs R; Kropp J; Runge R; Knapp FF; Franke WG
J Nucl Med; 2003 Jun; 44(6):953-60. PubMed ID: 12791825
[TBL] [Abstract][Full Text] [Related]
4. Systemic radionuclide therapy in pain palliation.
Liepe K; Runge R; Kotzerke J
Am J Hosp Palliat Care; 2005; 22(6):457-64. PubMed ID: 16323716
[TBL] [Abstract][Full Text] [Related]
5. Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer.
Maxon HR; Schroder LE; Thomas SR; Hertzberg VS; Deutsch EA; Scher HI; Samaratunga RC; Libson KF; Williams CC; Moulton JS
Radiology; 1990 Jul; 176(1):155-9. PubMed ID: 1693784
[TBL] [Abstract][Full Text] [Related]
6. The tolerance and therapeutic efficacy of rhenium-188 hydroxyethylidene diphosphonate in advanced cancer patients with painful osseous metastases.
Cheng A; Chen S; Zhang Y; Yin D; Dong M
Cancer Biother Radiopharm; 2011 Apr; 26(2):237-44. PubMed ID: 21539455
[TBL] [Abstract][Full Text] [Related]
7. Palliative treatment of painful disseminated bone metastases with 186Rhenium-HEDP in patients with lung cancer.
Leondi AH; Souvatzoglou MA; Rapti AS; Leontopoulou SA; Papadaki EK; Datseris EI; Anagnostopoulou US; Zerva CJ
Q J Nucl Med Mol Imaging; 2004 Sep; 48(3):211-9. PubMed ID: 15499295
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer.
de Klerk JM; van het Schip AD; Zonnenberg BA; van Dijk A; Quirijnen JM; Blijham GH; van Rijk PP
J Nucl Med; 1996 Feb; 37(2):244-9. PubMed ID: 8667053
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer.
Kolesnikov-Gauthier H; Carpentier P; Depreux P; Vennin P; Caty A; Sulman C
J Nucl Med; 2000 Oct; 41(10):1689-94. PubMed ID: 11037999
[TBL] [Abstract][Full Text] [Related]
10. Rhenium-188-HEDP therapy for the palliation of pain due to osseous metastases in lung cancer patients.
Zhang H; Tian M; Li S; Liu J; Tanada S; Endo K
Cancer Biother Radiopharm; 2003 Oct; 18(5):719-26. PubMed ID: 14629820
[TBL] [Abstract][Full Text] [Related]
11. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo.
Maxon HR; Schroder LE; Hertzberg VS; Thomas SR; Englaro EE; Samaratunga R; Smith H; Moulton JS; Williams CC; Ehrhardt GJ
J Nucl Med; 1991 Oct; 32(10):1877-81. PubMed ID: 1717669
[TBL] [Abstract][Full Text] [Related]
12. Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients.
Sciuto R; Festa A; Pasqualoni R; Semprebene A; Rea S; Bergomi S; Maini CL
Breast Cancer Res Treat; 2001 Mar; 66(2):101-9. PubMed ID: 11437096
[TBL] [Abstract][Full Text] [Related]
13. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases.
Liepe K; Kotzerke J
Nucl Med Commun; 2007 Aug; 28(8):623-30. PubMed ID: 17625384
[TBL] [Abstract][Full Text] [Related]
14. [Clinical experience with rhenium-188 HEDP therapy for metastatic bone pain].
Róka R; Séra T; Pajor L; Thurzó L; Láng J; Csernay L; Pávics L
Orv Hetil; 2000 May; 141(19):1019-23. PubMed ID: 10846424
[TBL] [Abstract][Full Text] [Related]
15. 186Re-HEDP for metastatic bone pain in breast cancer patients.
Lam MG; de Klerk JM; van Rijk PP
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S162-70. PubMed ID: 15118846
[TBL] [Abstract][Full Text] [Related]
16. Short- and long-term effects of 186Re-1,1-hydroxyethylidene diphosphonate in the treatment of painful bone metastases.
Sciuto R; Tofani A; Festa A; Giannarelli D; Pasqualoni R; Maini CL
J Nucl Med; 2000 Apr; 41(4):647-54. PubMed ID: 10768566
[TBL] [Abstract][Full Text] [Related]
17. The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain.
Liepe K; Runge R; Kotzerke J
J Cancer Res Clin Oncol; 2005 Jan; 131(1):60-6. PubMed ID: 15449184
[TBL] [Abstract][Full Text] [Related]
18. 186Re-etidronate. Efficacy of palliative radionuclide therapy for painful bone metastases.
Han SH; De Klerk JM; Zonnenberg BA; Tan S; Van Rijk PP
Q J Nucl Med; 2001 Mar; 45(1):84-90. PubMed ID: 11456380
[TBL] [Abstract][Full Text] [Related]
19. Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDP. Clinical benefit in a real-world study.
Lange R; Overbeek F; de Klerk JM; Pasker-de Jong PC; van den Berk AM; Ter Heine R; Rodenburg CJ; Kooistra A; Hendrikse NH; Bloemendal HJ
Nuklearmedizin; 2016 Sep; 55(5):188-95. PubMed ID: 27443809
[TBL] [Abstract][Full Text] [Related]
20. Palliative analgesic effect of Re-186 HEDP in various cancer patients with bone metastases.
Küçük NO; Ibiş E; Aras G; Baltaci S; Ozalp G; Bedük Y; Canakci N; Soylu A
Ann Nucl Med; 2000 Aug; 14(4):239-45. PubMed ID: 11023023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
